With Investors' Eyes On Biotechs, Biotechs Must Keep Their Eyes On Transparency

By Darcy Grabenstein

If recent pharmaceutical mergers and acquisitions are any indication, 2019 is poised to marked by industry deal-making. Earlier this month, the J.P. Morgan Healthcare Conference coincided with Eli Lilly & Co.’s $8 billion acquisition of Loxo Oncology Inc. The news came on the heels of the $74 billion merger of Bristol-Myers Squibb and Celgene, and the $5.1 billion acquisition of Tesaro Inc. by GlaxoSmithKline PLC.